Lentiviral-Mediated Systemic RNA Interference In Vivo.

Area of Science:

• Biotechnology
• Gene Therapy
• Immunology

Background:

• Short hairpin RNA (shRNA)-encoding lentivirus is a key tool for gene manipulation in preclinical research.
• Lentiviral vectors efficiently transduce immune and hematopoietic stem cells, crucial targets for autoimmune disease therapies.
• Gene manipulation of these cells is often challenging with conventional methods.

Purpose of the Study:

• To describe the systemic in vivo application of lentivirus for gene transfer.
• To provide methods for viral quantification and tracking after administration.
• To establish protocols for preclinical gene therapy studies.

Main Methods:

• Production of concentrated shRNA-encoding lentiviral particles (described previously).
• Systemic in vivo administration via intraperitoneal injection.
• Quantification of lentivirus before injection and integrated provirus post-injection.

Main Results:

• Demonstration of a complete workflow for in vivo lentiviral gene transfer.
• Establishment of methods for accurate viral load assessment.
• Validation of lentiviral transduction in target cells within a living organism.

Conclusions:

• Systemic in vivo lentiviral application is a feasible and effective strategy for preclinical gene therapy.
• Accurate viral quantification is essential for reproducible and safe gene transfer studies.
• This methodology facilitates the advancement of gene-based treatments for autoimmune diseases.